close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.33 +0.39 (+0.84%)
Streaming Delayed Price Updated: 3:01 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
82 83 Next >
News headline image
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Stock I Wouldn't Touch With a 10-Foot Pole ↗
This stock isn't as safe as it seems, and now isn't the time to dabble. 
Via The Motley Fool
News headline image
3 Bargain Stocks to Buy Now: May 2024 ↗
These bargain stocks to buy provide substantial upside since they are trading at a significant discount to their historical multiples. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
News headline image
Is Bristol Myers' Dividend in Danger? ↗
Should investors brace for a dividend cut? 
Via The Motley Fool
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys. 
Via MarketBeat
News headline image
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst ↗
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,... 
Via Benzinga
News headline image
Walmart Earnings And The State Of The Consumer ↗
​​​​​​​This earnings season showed a notable acceleration in the earnings growth pace, which produces a reassuring earnings backdrop for the market. 
Via Talk Markets
News headline image
2 Beaten-Down Stocks to Buy and Hold for 10 Years ↗
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
News headline image
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma ↗
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high... 
Via Benzinga
News headline image
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
News headline image
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders ↗
Using these capture-the-dividend stock strategy for tactical traders can be profitable with high-yield blue-chips. 
Via InvestorPlace
News headline image
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
News headline image
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip ↗
Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely. 
Via MarketBeat
Topics Economy
News headline image
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday? ↗
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
News headline image
Catalyst's New CEO Has Big Ideas For The Small Biotech ↗
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
News headline image
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
News headline image
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields ↗
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today